Search Results
Your search for Julia Cipriano, MS ,Julia Cipriano, MS matches 42 pages
Showing 1 - 42Prophylactic Surgical Menopause for Women With Familial Risk of Ovarian Cancer: Impact on Coronary Artery Calcium Development
The results of the HARMOny study published in JACC: CardioOncology by Beekman et al did not reveal a long-term adverse effect of prophylactic surgical menopause on the development of coronary artery calcium—a marker of cardiovascular disease risk—in women with a high familial risk of ovarian...
AI and the Future of Lung Cancer Screening: Still Room for Improvement
“Artificial intelligence [AI] will be used in all aspects of [lung cancer] screening…, and it continues to get better,” commented topic overview speaker David F. Yankelevitz, MD, Professor of Radiology at the Icahn School of Medicine at Mount Sinai, New York, at the Quantitative Imaging Workshop...
Evidence-Based Recommendations and Knowledge Gaps Regarding Cardio-Oncology
A recent report highlighted evidence-based recommendations for the prevention, detection, and management of cancer therapy–related cardiovascular toxicity and cardiovascular events in patients with cancer, as well as knowledge gaps. Select considerations are summarized herein. “The European Society ...
Impact of Food Insecurity on the Incidence of Hepatocellular Carcinoma
At the 2024 American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Rebecca D. Kehm, PhD, of Columbia University Mailman School of Public Health, New York, and colleagues presented some of the ...
Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer
Based on results from the ongoing multicenter phase III CHIPOR trial, which were reported in The Lancet Oncology Jean-Marc Classe, MD, PhD, Head of the Oncological Surgery Department at the Institut de Cancérologie de l’Ouest, Saint Herblain, France, and colleagues, the addition of hyperthermic...
Determining the Optimal First-Line Management of Advanced Classical Hodgkin Lymphoma
“While clinical trials emphasize improvement in cure rates for patients with advanced classical Hodgkin lymphoma, an important goal is reducing the potential long-term effects of treatment,” commented Iris Isufi, MD, of the Smilow Cancer Hospital and Yale Cancer Center, New Haven, Connecticut, and ...
4-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
Neoadjuvant chemotherapy with vs without the PD-1 inhibitor nivolumab conferred a higher pathologic complete response rate and long-term event-free survival benefit in Asian patients with resectable non–small cell lung cancer (NSCLC), according to the global phase III CheckMate 816 trial. At the...
Exploring Issues in Oncofertility
“Cancer in young adults is more complicated in part [because of the risk of] infertility and premature menopause,” commented Ann H. Partridge, MD, MPH, FASCO, Interim Chair, Department of Medical Oncology; the Eric P. Winer, MD Chair in Breast Cancer Research, Dana-Farber Cancer Institute; and ...
TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC
The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC
The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
EMBER: Imlunestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
In the the phase IA/B dose-escalation and -expansion EMBER study reported in the Journal of Clinical Oncology by Jhaveri et al, the next-generation oral selective estrogen receptor degrader imlunestrant (alone and in combination with other targeted therapies) demonstrated a manageable safety...
CABINET Trial Supports Multitargeted Tyrosine Kinase Inhibitor for Advanced Neuroendocrine Tumors
As reported in The New England Journal of Medicine by Chan et al, the multicenter phase III CABINET trial has shown significantly improved progression-free survival with the multitargeted tyrosine kinase inhibitor cabozantinib vs a placebo in previously treated patients with progressive, advanced...
AEGEAN Update Confirms Benefit of Perioperative Durvalumab in Resectable NSCLC
The second planned interim analysis of the global phase III AEGEAN trial—reported by John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer...
NURE-Combo: First Results for a Perioperative Chemoimmunotherapy Approach in Muscle-Invasive Bladder Cancer
Based on the first results of the single-center phase II NURE-Combo trial, which were reported in the Journal of Clinical Oncology (JCO) by Mercinelli et al, the combination of neoadjuvant nivolumab plus nab-paclitaxel followed by postsurgical adjuvant nivolumab appeared to be safe and active in...
Taletrectinib in ROS1-Positive NSCLC: Focus on Prior Tyrosine Kinase Inhibitor Exposure Status
Updated data from the global, multicenter, single-arm phase II TRUST-II trial, which were reported by Liu et al during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract MA06.03), continued to demonstrate robust overall and...
Study Supports Universal Genetic Testing of Newly Diagnosed Patients With Invasive Breast Cancer
In a cross-sectional study reported in JAMA Network Open, Rezoug et al found that universal genetic testing identified immediately actionable and established germline pathogenic variants in more than 1 in 20 newly diagnosed patients with invasive breast cancer and was associated with systemic...
Delays in Oral Antimyeloma Treatment Initiation: Role of Social Determinants of Health
A retrospective cohort study published in Blood Cancer Journal by Gasoyan et al revealed discrepancies between the timing of the initiation of any treatment and the fill of prescriptions for oral antimyeloma medications in patients with multiple myeloma, with a lower likelihood of Black and older...
Early-Onset Colorectal Cancer: Rurality and Poverty May Be Linked to Lower Survival
Patients with early-onset colorectal cancer living in rural vs urban areas were found to have a lower likelihood of 5-year survival, with persistent poverty compounding this association in some age groups, according to an analysis published in a research letter by Tsai et al in JAMA Network Open....
Impact of Breast Cancer Screening Interval on Stage at Diagnosis and Overall Survival
Annual mammographic screening appeared to be associated with a reduced risk of late-stage breast cancer and an overall survival benefit across clinical and demographic subgroups of patients older than age 40, according to an observational analysis reported by Zuley et al in the Journal of Clinical...
Remembering a Pioneer in Melanoma and Immunotherapy: Jeffrey S. Weber, MD, PhD, FASCO
Jeffrey S. Weber, MD, PhD, FASCO, an internationally recognized pioneer in melanoma and cancer immunotherapy, died on August 19, 2024, according to an announcement from the Melanoma Research Foundation. He most recently served as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at...
The Evolving Epidemiology of Gastrointestinal Stromal Tumors in Major Organ Sites
Based on a descriptive, U.S. population–based cohort study reported in JAMA Network Open by Alvarez et al, over the past 2 decades, the incidence of gastrointestinal stromal tumors in major organ sites has increased among several patient populations. The findings may assist in directing future...
Role of Patient-Reported Outcome Measures in Assessing Chemotherapy-Induced Peripheral Neuropathy
A cohort study reported in JAMA Network Open by Li et al demonstrated the superiority of patient-reported outcome measures vs other methods in assessing nerve damage in patients with cancer who underwent neurotoxic chemotherapy. “Accordingly, the adoption of chemotherapy-induced peripheral...
Breast Cancer Index Confirmed as Prognostic in a SOFT Trial–Derived Population
A prospective-retrospective translational study reported in JAMA Oncology by Ruth M. O’Regan, MD, and colleagues confirmed the prognostic value of the Breast Cancer Index (BCI) in a Suppression of Ovarian Function Trial (SOFT) trial–derived population of premenopausal women with early-stage,...
Risk of Suicidal Behavior Among Spouses of Patients With Cancer
The risk of suicidal behavior may be increased among the spouses of patients with cancer, according to a retrospective Danish population-based cohort study reported by Liu et al in JAMA Oncology. Clinical and societal awareness was thus deemed essential, particularly during the first year after...
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.1...
Heart-Sparing Radiation Therapy Technique in Left-Sided Breast Cancer: Benefits and Costs
A model-based analysis reported in JACC: CardioOncology by Busschaert et al suggested that the heart-sparing deep inspiration breath-hold vs free-breathing radiation therapy technique is cost-effective—despite increasing treatment time—and may improve the long-term cardiovascular health of patients ...
Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality?
The results of a contemporary U.S. population–based cohort study published by Giannakeas et al in JAMA Oncology revealed that patients with unilateral breast cancer had an increased risk of breast cancer–related death after developing contralateral disease. Although the findings also showed a...
Patients With Prostate Cancer: Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes
Based on the results of a retrospective cohort study published by Demissei et al in JACC: CardioOncology, Black patients with prostate cancer who received systemic androgen-deprivation therapy (ADT) seemed to have a significantly greater likelihood of experiencing adverse cardiovascular disease...
Does Neighborhood Walkability Impact the Burden of Cardiovascular Risk Factors in Patients With Cancer?
The results of a cross-sectional study reported in JACC: CardioOncology by Nwana et al revealed a significant association between the extent to which a neighborhood facilitates walking and the burden of modifiable cardiovascular risk factors among patients with a history of cancer. “[The findings...
Immunotherapy-Induced Multiorgan Immune-Related Adverse Events: Co-occurrence Patterns and Prognostic Implications
The results of a retrospective multicohort study, reported in The Lancet Oncology by Wan et al, suggested that the identification of the immune-related adverse event cluster to which a patient belongs may aid in prognosticating response to immunotherapy. “These insights can be leveraged to counsel...
How Does Endometriosis Typology Influence Ovarian Cancer Risk?
In a Utah population–based cohort study reported in JAMA Network Open, Barnard et al found that women with ovarian endometriomas and/or deep-infiltrating endometriosis had a markedly increased risk of developing ovarian cancer. Those with such severe subtypes may represent an important population...
Can GLP-1 Receptor Agonists Prevent Obesity-Associated Cancers in Patients With Type 2 Diabetes?
Based on the results of a retrospective U.S. population–based cohort study, which were reported in JAMA Network Open by Wang et al, treatment with glucagon-like peptide 1 (GLP-1) receptor agonists vs insulins seemed to be associated with a decreased risk of developing specific obesity-associated...
Nasopharyngeal Carcinoma: Adding Sintilimab to Standard Chemoradiotherapy for Locoregionally Advanced Disease
Based on the results of the Chinese multicenter phase III CONTINUUM trial, which were reported in The Lancet by Liu et al, the addition of the PD-1 inhibitor sintilimab to standard chemoradiotherapy seemed to improve event-free survival—albeit with more frequent but manageable adverse events—in...
Risk of Adverse Obstetric Outcomes in Adolescent and Young Adult Cancer Survivors
In an English and Welsh study (The Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Sunguc et al found that cervical cancer and leukemia survivors have a heightened risk of experiencing several serious obstetric complications. “Therefore, any pregnancy [in these...
Nonplatinum Chemotherapy Regimen for Advanced Cholangiocarcinoma
Based on the results of the multicenter phase II NIFE-AIO-YMO HEP-0315 trial, which were reported in the Journal of Clinical Oncology by Ettrich et al, first-line palliative treatment with nanoliposomal irinotecan plus fluorouracil and leucovorin appears to be safe and active in patients with...
Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP
As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma
As reported at the 2024 ASCO Annual Meeting (Abstract 9500) and in The New England Journal of Medicine by Georgina V. Long, MD, PhD, and colleagues, the final, 8-year follow-up analysis of the phase III COMBI-AD trial has shown continued improvements in relapse-free and distant metastasis–free...
Socioeconomic Disparities in Quality of Life After Early-Stage Breast Cancer Diagnosis
As reported in the Journal of Clinical Oncology by Sandoval et al, after a diagnosis of early-stage breast cancer, the magnitude of preexisting socioeconomic status–related inequalities in quality of life increased over time for patients in the multicentric French CANTO cohort. “When we talk about ...
Advanced Neuroendocrine Tumors: Adding Lu-177 Dotatate to Standard First-Line Therapy
As reported in The Lancet by Simron Singh, MD, MPH, FRCPC, and colleagues, primary results of the international, multicenter, randomized phase III NETTER-2 study have shown significantly improved progression-free survival with the addition of the radioligand lutetium-177 dotatate (Lu-177 dotatate)...
NCCN Clinical Practice Guidelines in Oncology: 2024 Updates
The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...
